Markozashvili Diana, Ribrag Vincent, Vassetzky Yegor S
UMR 8126 CNRS, Univ Paris-Sud, Université Paris-Saclay, Institut Gustave Roussy, 94805, Villejuif, France.
LIA1066 « Laboratoire franco-russe de recherche en oncologie », Villejuif, France.
Invest New Drugs. 2015 Dec;33(6):1280-91. doi: 10.1007/s10637-015-0290-y. Epub 2015 Sep 30.
A vast majority of lymphomas and leukaemias are results of translocations. These translocations produce various genetic and epigenetic changes that lead to oncogenesis. This opens an opportunity to use a relatively new class of anti-cancer agents, inhibitors of histone deacetylases (HDACi) to target lymphoid malignancies. Surprisingly, the rational basis for treatment of lymphomas with HDACi is far from clear, although some positive results have been obtained. Here we analyze the effect of histone deacetylase (HDAC) inhibitors on lymphoid malignancies.
绝大多数淋巴瘤和白血病是易位的结果。这些易位会产生各种遗传和表观遗传变化，从而导致肿瘤发生。这为使用一类相对较新的抗癌药物——组蛋白去乙酰化酶抑制剂（HDACi）来靶向淋巴恶性肿瘤提供了机会。令人惊讶的是，尽管已经取得了一些积极成果，但使用HDACi治疗淋巴瘤的合理依据仍远未明确。在此，我们分析了组蛋白去乙酰化酶（HDAC）抑制剂对淋巴恶性肿瘤的影响。
